These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29707870)

  • 1. Polypeptides with High Zwitterion Density for Safe and Effective Therapeutics.
    Zhang P; Jain P; Tsao C; Yuan Z; Li W; Li B; Wu K; Hung HC; Lin X; Jiang S
    Angew Chem Int Ed Engl; 2018 Jun; 57(26):7743-7747. PubMed ID: 29707870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
    Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
    Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
    Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
    Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyethylene Glycol-Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart.
    Ozer I; Kelly G; Gu R; Li X; Zakharov N; Sirohi P; Nair SK; Collier JH; Hershfield MS; Hucknall AM; Chilkoti A
    Adv Sci (Weinh); 2022 Apr; 9(11):e2103672. PubMed ID: 35133079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological properties of uricase conjugated to neutral soluble polymers.
    Caliceti P; Schiavon O; Veronese FM
    Bioconjug Chem; 2001; 12(4):515-22. PubMed ID: 11459455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers.
    Caliceti P; Schiavon O; Veronese FM
    Bioconjug Chem; 1999; 10(4):638-46. PubMed ID: 10411462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase.
    Tsuji J; Hirose K; Kasahara E; Naitoh M; Yamamoto I
    Int J Immunopharmacol; 1985; 7(5):725-30. PubMed ID: 2412977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant.
    Zhang C; Fan K; Luo H; Ma X; Liu R; Yang L; Hu C; Chen Z; Min Z; Wei D
    Int J Pharm; 2012 Jul; 430(1-2):307-17. PubMed ID: 22503989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase.
    Savoca KV; Davis FF; Palczuk NC
    Int Arch Allergy Appl Immunol; 1984; 75(1):58-67. PubMed ID: 6746105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine).
    Schiavon O; Caliceti P; Ferruti P; Veronese FM
    Farmaco; 2000 Apr; 55(4):264-9. PubMed ID: 10966157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
    Feng J; Li X; Yang X; Zhang C; Yuan Y; Pu J; Zhao Y; Xie Y; Yuan H; Bu Y; Liao F
    Arch Pharm Res; 2010 Nov; 33(11):1761-9. PubMed ID: 21116779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive study of the drug delivery properties of poly(l-lactide)-poly(ethylene glycol) nanoparticles in rats and tumor-bearing mice.
    Shalgunov V; Zaytseva-Zotova D; Zintchenko A; Levada T; Shilov Y; Andreyev D; Dzhumashev D; Metelkin E; Urusova A; Demin O; McDonnell K; Troiano G; Zale S; Safarovа E
    J Control Release; 2017 Sep; 261():31-42. PubMed ID: 28611009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
    Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
    Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
    Feeney OM; Williams HD; Pouton CW; Porter CJ
    J Control Release; 2014 Oct; 192():219-27. PubMed ID: 25058571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity.
    Zhang P; Sun F; Tsao C; Liu S; Jain P; Sinclair A; Hung HC; Bai T; Wu K; Jiang S
    Proc Natl Acad Sci U S A; 2015 Sep; 112(39):12046-51. PubMed ID: 26371311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomes modified with superhydrophilic polymer linked to a nonphospholipid anchor exhibit reduced complement activation and enhanced circulation.
    Nag OK; Yadav VR; Croft B; Hedrick A; Awasthi V
    J Pharm Sci; 2015 Jan; 104(1):114-23. PubMed ID: 25393628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Species and sex differences in the blood clearance and immunogenicity of PEGylated uricase: A comparative 26-week toxicity study in rats and monkeys.
    Zhang C; Fan K; Luo H; Cheng Y; Lu Y; Zheng J; Chen Z; Xue J; Zhao Q; Zhang M; Ge Y; Hu C; Bai Y; Yang L; Ma X; Chen M; Zhao Z; Shi X
    Life Sci; 2020 Aug; 255():116892. PubMed ID: 31610209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and biopharmaceutical properties of macromolecular conjugates of uricase with dextran and polyethylene glycol.
    Yasuda Y; Fujita T; Takakura Y; Hashida M; Sezaki H
    Chem Pharm Bull (Tokyo); 1990 Jul; 38(7):2053-6. PubMed ID: 1702692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of poly(hydroxyethyl-l-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration.
    Romberg B; Oussoren C; Snel CJ; Carstens MG; Hennink WE; Storm G
    Biochim Biophys Acta; 2007 Mar; 1768(3):737-43. PubMed ID: 17223070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics.
    Verhoef JJ; Carpenter JF; Anchordoquy TJ; Schellekens H
    Drug Discov Today; 2014 Dec; 19(12):1945-52. PubMed ID: 25205349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.